Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma.
Ozgen
Metin
M
Koca
Suleyman S
SS
Isik
Ahmet
A
Ozercan
Ibrahim H
IH
D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects*; D004195:Disease Models, Animal; D005355:Fibrosis; D007274:Injections, Intraperitoneal; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D001761:Bleomycin; D008727:Methotrexate